International Clinics
Daily
Daraxonrasib plus chemotherapy shrank tumours in 61% of patients with advanced pancreatic cancer in an early trial
Results presented at ENA 2026 in Barcelona tested adding the daily pill daraxonrasib to first-line chemotherapy for metastatic pancreatic cancer.
